To The Moon

I. Transaction Core Details (As of April 20, 2026)

• Latest Update: Definitive agreement officially announced (total deal value up to $7 billion, including upfront cash plus R&D milestone payments).

• Structure: Cash upfront combined with milestone payments, consistent with Lilly’s long-standing M&A strategy to mitigate early-stage development risks.

• Expected Close: Scheduled for the second half of 2026, subject to standard regulatory approvals.

II. Strategic Impact Analysis

1. Business: Filling the Oncology Pipeline, Reducing Concentration Risk

• Core Asset: Kelonia’s proprietary in vivo CAR-T platform (iGPS) — an engineered lentiviral particle system that modifies T-cells directly in the body, eliminating the need for apheresis, ex vivo manufacturing or lymphodepletion, thus streamlining treatment vs. traditional ex vivo CAR-T.

• Lead Candidate: KLN-1010, a BCMA-targeting therapy for multiple myeloma currently in Phase 1; initial clinical data was presented at the 2025 ASH Annual Meeting, showing 100% MRD-negative response rate in 4 patients with favorable safety profile, with additional data expected in H2 2026.

• Strategic Significance: Diversifies Lilly’s revenue away from its GLP-1 franchise, strengthening its oncology footprint to balance portfolio concentration and reduce over-reliance on metabolic drugs.

2. Valuation: Near-Term Cash Flow Impact, Long-Term Value Accretion

• Near-term: The upfront payment will cause a substantial cash outflow, weighing on the balance sheet in the short term, and will be treated as a strategic R&D investment.

• Long-term: The market will price in the future pipeline optionality of Kelonia’s iGPS platform; the acquisition reinforces Lilly’s premium valuation, supported by its robust cash generation capacity.

III. $礼来(LLY)$ 2026 Stock Outlook

1. Fundamental Support

• GLP-1 Franchise: Orforglipron (Foundayo), an oral GLP-1, was approved on April 1, 2026; it is now in the early commercial launch phase with manufacturing scale-up underway. Additionally, $礼来(LLY)$ has agreed to offer discounted prices for its GLP-1 drugs to some Medicare enrollees, expanding access to millions more Americans.

• M&A Capacity: Strong operating cash flows support continued bolt-on acquisitions; the Kelonia deal follows a string of recent biotech acquisitions (e.g., Prevail, DICE), demonstrating Lilly’s aggressive expansion strategy.

2. Key Risks

• Clinical Risk: Kelonia’s iGPS platform remains in early-stage development (Phase 1); while initial data is promising, further proof-of-concept data is still pending to validate its commercial potential.

• Pricing Risk: GLP-1 pricing pressure persists from Medicare negotiation — Lilly agreed to sell Zepbound to some Medicare enrollees for $245 per month, about 55% of current Medicaid and Medicare net prices, which may impact margins.

• Competitive Risk: Intensifying competition in the obesity/diabetes space from Novo Nordisk (Wegovy/Ozempic), Pfizer, and AstraZeneca could erode market share.

3. Technical Levels & Analyst Views

• Price Action: Trading in the ~$939 range in recent sessions; MACD indicator shows potential bullish momentum building.

• Support/Resistance: Key support level at ~$820; strong resistance at ~$1,044.

• Consensus: 31 analysts cover $礼来(LLY)$ , with an updated average price target of $1,266.31 (~36% upside); 89.47% of analysts recommend “Buy” or “Strong Buy” ratings, reflecting broad bullish sentiment.

• Notable Targets: Morgan Stanley sets a target of $1,327; the latest Street-high upgrades reflect optimism around Orforglipron’s launch and Kelonia’s pipeline potential, with the highest analyst target reaching $1,500.